FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma

Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

The current status of multiple myeloma diagnosis and treatment